Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 9:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 1,487 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Standard Scheduling Clear all

Conditions: Widspread Chronic Pain, Fibromyalgia
Interventions: Vagal nerve stimulation through deep exhalation exercise, Vagal nerve stimulation through ear electrical stimulation, No intervention (observational study); Other
Lead sponsor: University of North Georgia; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Dahlonega, Georgia

Conditions: Thyroid Cancer
Interventions: IMRT, DWI MRI, Doxorubicin, Modified Barium Swallow Impairment Profile (MBSImP); Radiation · Device · Drug + 1 more
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 6
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more

Conditions: Hypertension
Interventions: carvedilol; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 80 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Acute Lung Injury
Interventions: Diuresis (furosemide) part I, Fluid Bolus (crystalloid or albumin), Vasopressors (Norepinephrine, Vasopressin, Phenylephrine, Epinephrine), Dobutamine, Concentrate all drips and nutrition, Diuresis (furosemide) part II, Dialysis; Drug · Other · Procedure
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 3
States / cities: Clackamas, Oregon • Portland, Oregon

Conditions: Frequent Relapsing Nephrotic Syndrome, Steroid Dependent Nephrotic Syndrome
Interventions: Rituximab, MMF; Drug
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 1 Year to 18 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Diabetic Foot Ulcers, Venous Ulcers, Pressure Ulcers
Interventions: Autologous PRP Gel, Autologous PRP Injections, Autologous PRP Gel plus PRP Injections, Standard Wound Care; Device · Procedure
Lead sponsor: Arteriocyte, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 6
States / cities: Bakersfield, California • Idaho Falls, Idaho • Englewood, New Jersey + 3 more

Conditions: Stroke
Interventions: VIRTUAL, Standard care; Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 542 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hemodialysis
Interventions: Novel Physical Activity Program, Standard of Care Physical Activity Program; Behavioral
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 3
States / cities: Bolingbrook, Illinois • Oak Brook, Illinois • Urbana, Illinois

Conditions: Tissue Expansion, Breast Reconstruction
Interventions: Tissue Expansion; Procedure
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Perineal Injury, Pain Vulva, Perineum; Injury
Interventions: Perineal ice packs, medicated witch-hazel pads, and topical benzocaine spray; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older · Female only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Open Wound, Wound Heal
Interventions: Micro/nanobubble (MNB) - Irrigation, 0.9% Normal Saline - Irrigation, Micro/nanobubble (MNB) - Negative Pressure Wound Therapy with Instillation (NPWTi), 0.9% Normal Saline - Negative Pressure Wound Therapy with Instillation (NPWTi); Drug · Other
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Orange, California

Conditions: Merkel Cell Carcinoma
Interventions: Avelumab, Comprehensive Ablative Radiation Therapy; Drug · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma, Basal Cell Carcinoma
Interventions: Copaxone; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 3
States / cities: Fairway, Kansas • Kansas City, Kansas

Conditions: Geriatric Hip Fracture
Interventions: XR™ Recovery Supplement, XR Carbohydrate Loading Supplement; Dietary Supplement
Lead sponsor: NYU Langone Health; Other
Eligibility: 65 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Aromatase Inhibitor, Musculoskeletal Symptoms, Postmenopausal Breast Cancer Survivors
Interventions: APA, Sham APA control, Education control; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Primary Care Appointment Keeping
Interventions: Enhanced contact plus behavioral skills, Enhanced contact only, Standard of Care; Behavioral
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 18 Years and older
Enrollment: 1,838 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 6
States / cities: Birmingham, Alabama • Miami, Florida • Baltimore, Maryland + 3 more

Conditions: Breast Neoplasms
Interventions: SU011248, Chemotherapy; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 77
States / cities: Corona, California • Fullerton, California • Glendora, California + 59 more

Conditions: Corneal Neovascularization, Corneal Graft Failure
Interventions: Avastin® (bevacizumab), 0.9% NaCl & Refresh Liquigel; Drug
Lead sponsor: Reza Dana, MD; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hearing Loss
Interventions: Health and Wellness Coaching; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 85 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Malignant Glioma
Interventions: Palonosetron (PALO); Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Diabetes Mellitus, Type 2, Hypertension
Interventions: EXTEND Plus, EXTEND; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 30 Years to 75 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Epithelial Ovarian Carcinoma
Interventions: Metformin, Paclitaxel, Carboplatin; Drug
Lead sponsor: Gynecologic Oncology Associates; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Basal Cell Carcinoma, Squamous Cell Carcinoma
Interventions: electronic brachytherapy; Radiation
Lead sponsor: Xoft, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 5
States / cities: Tuscaloosa, Alabama • Casa Grande, Arizona • Scottsdale, Arizona + 2 more

Conditions: Kidney Failure, Kidney Transplant; Complications, Chimera
Interventions: Bone Marrow Transplant, Peripheral Blood Stem Cell Collection, Fludarabine, Cyclophosphamide, Rituximab, Siplizumab; Other · Procedure · Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

The Effect of Vagus Nerve Stimulation on Pain and Functional Activities in Individuals With Chronic Widespread Pain

Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Non-Anaplastic Non-Medullary Thyroid Cancer

Conditioned Pharmacotherapeutic Effects in Hypertension

Hemodynamics and Extravascular Lung Water in Acute Lung Injury

Randomized Trial Comparing Rituximab Against Mycophenolate Mofetil in Children Wtih Refractory Nephrotic Syndrome

Registry Trial of the Effectiveness of Platelet Rich Plasma for Chronic Non-Healing Wounds

Video-based Intervention to Address Disparities in Blood Pressure Control After Stroke

Patient-Centered Physical Activity Program for Hemodialysis Patients

Patient Performed Tissue Expansion for Two-stage Alloplastic Breast Reconstruction

Improving Postoperative Recovery: A Study of Multimodal Perineal Analgesia Protocol (MPAP) After Vaginal Surgery

Micro/Nanobubbles (MNBs) for Treatment of Acute and Chronic Wounds

Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma

A Window of Opportunity Trial of Intratumoral Injection of Copaxone® in Patients With Percutaneously Accessible Tumors

Nutritional Supplementation in Geriatric Hip Fractures

Auricular Point Acupressure to Self-Manage Chronic Pain or Aromatase Inhibitor Musculoskeletal Symptoms in Breast Cancer Survivors: Effectiveness and Scientific Underpinnings

Intervention to Retain HIV-positive Patients in Medical Care

Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer

Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival

A System and Process to Improve the Satisfaction With Hearing Health Products

Intravenous Palonosetron With Radiotherapy and Concomitant Temozolomide

Expanding Technology-Enabled Nurse Delivered Chronic Disease Care

Study of Paclitaxel, Carboplatin and Oral Metformin in the Treatment of Advanced Stage Ovarian Carcinoma

Electronic Brachytherapy for the Treatment of NMSC

Delayed Tolerance Through Mixed Chimerism